Crinetics Pharmaceuticals (CRNX) Accounts Payables (2017 - 2026)

Crinetics Pharmaceuticals' Accounts Payables history runs 10 years deep, the most recent figure standing at $37.5 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 18.57% year-over-year to $37.5 million; the TTM figure through Mar 2026 stood at $37.5 million (up 18.57% YoY), while the FY2025 annual figure was $41.8 million, up 94.56% from the prior year.
• Accounts Payables for Q1 2026 stood at $37.5 million, down from $41.8 million in the prior quarter.
• The five-year high for Accounts Payables was $41.8 million in Q4 2025, with the low at $4.9 million in Q3 2024.
• The 5-year median for Accounts Payables is $21.9 million (2023), against an average of $22.1 million.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables tumbled 77.48% in 2024, then jumped 581.8% in 2025.
• Crinetics Pharmaceuticals' Accounts Payables stood at $6.9 million in 2022, then surged by 237.0% to $23.2 million in 2023, then decreased by 7.45% to $21.5 million in 2024, then jumped by 94.56% to $41.8 million in 2025, then decreased by 10.25% to $37.5 million in 2026.
• Business Quant data shows CRNX's Accounts Payables at $37.5 million in Q1 2026, $41.8 million in Q4 2025, and $33.7 million in Q3 2025.